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While female sex is a risk factor for torsades de pointes,1 29-44% of drug-induced cases 
occur in men.2,3 Older age is also a risk factor.1 Preclinical studies have shown that 
testosterone and progesterone protect against drug-induced prolongation of ventricular 
repolarization, early afterdepolarizations and arrhythmias.4 Oral progesterone shortens QT 
intervals and attenuates drug-induced QT lengthening in young women.5 We hypothesized 
that transdermal testosterone and oral progesterone attenuate drug-induced QT interval 
lengthening in older men.
This prospective, randomized, double-blind, placebo-controlled three-way crossover-design 
study was approved by the Indiana University IRB and conducted from July 2015 – October 
2017 (ClinicalTrial.gov Identifier: ). Exclusion criteria: history of prostate or breast cancer; 
benign prostatic hyperplasia; weight <60 or >135 kg; potassium <3.6 mEq/L; magnesium 
<1.8 mg/dL; hematocrit <26%; hepatic transaminases >3x ULN; baseline Bazett’s-corrected 
QTc >450 ms; heart failure (LVEF <40%); family/personal history of long QT syndrome, 
arrhythmias or sudden cardiac death; permanently paced ventricular rhythm; taking QT-
prolonging drugs or strong CYP3A inhibitors. Subjects provided written informed consent.
Men ≥ 65 years of age received, for 7 days, in randomized order: a) Transdermal 
testosterone 100mg (1% Androgel®) every morning and 2 placebo capsules every evening, 
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b) Oral progesterone 400mg (2×200mg capsules, Teva Pharmaceuticals) every evening and 
placebo transdermal gel every morning, or c) Placebo transdermal gel every morning and 2 
placebo capsules every evening.
On the morning after the 7th day, subjects received a 10-minute intravenous infusion of the 
QT-lengthening drug ibutilide (0.003 mg/kg). Three 12-lead ECGs were obtained ~ 1 minute 
apart at baseline (pre-ibutilide), end-of-infusion, and at 5, 10, 15, 20, 30, and 45 minutes and 
1, 2, 4, 6, and 8 hours post-infusion. Lead II QT intervals were measured by one investigator 
(blinded to treatment phases) using computerized high-resolution electronic calipers and the 
tangent method. QT and RR intervals were averaged over 3 consecutive complexes. QT 
intervals were Fridericia (QTF)- and Framingham (QTFram)-corrected. Linear mixed effects 
modeling was performed, where treatment arms and time periods were fixed effects and the 
subjects were random effects. When overall p values were significant, pairwise comparisons 
were performed. Serum concentration data were log-transformed.
Seventy-seven subjects were screened; 16 declined and 39 met ≥1 exclusion criterion. 
Twenty-two subjects consented; 8 subsequently met ≥1 exclusion criterion. Fourteen 
subjects were enrolled and completed all study phases. Mean age: 73±6 years (65-86); 13 
white, 1 black. Mean weight: 90±16 kg; mean ibutilide dose: 0.27±0.05 mg. There was no 
significant difference in median (IQR) maximum serum ibutilide concentration between the 
testosterone, progesterone and placebo phases [955 (679, 1921) vs 1135 (632, 1526) vs 885 
(646, 1430) pg/mL, p=0.82]. Median serum testosterone concentration was higher during the 
testosterone phase [678 (430,1017) vs 258 (227, 276) vs 272 (219,335) ng/dL, p<0.001]. 
Median serum progesterone concentration was higher during the progesterone phase [18.9 
(15.3,23.7) vs 0.45 (0.30,0.60) vs 0.40 (0.30,0.60) ng/mL, p<0.001].
Median pre-ibutilide heart rates (HRs) during testosterone, progesterone and placebo phases 
were 57 (54, 67) vs 60 (53, 65) vs 58 (55, 66) bpm (p=0.99). HRs were similar, and not 
significantly different across treatment phases, at the end-of-infusion and one-hour post-
infusion. Post-ibutilide QTF and QTFram during testosterone, progesterone and placebo 
phases are presented in Figure 1, panels A&B. Pre-ibutilide QTF and QTFram were not 
significantly different between the testosterone, progesterone or placebo phases (QTF: 
393±19 vs 399±16 vs 399±13 ms, p=0.09; QTFram: 392±19 vs 397±12 vs 397±18 ms, 
p=0.22). Maximum post-ibutilide QTF and QTFram intervals were lowest during the 
testosterone phase (Figure 1, panels C&D). There was no significant difference in maximum 
QTF or QTFram between progesterone and placebo.
Transdermal testosterone decreased the area under the QT interval effect curves (AUEC) 
one-hour post-ibutilide (AUEC0-1.17, accounting for the 10-minute infusion) compared to 
progesterone and placebo (QTF: 471±24 vs 480±24 vs 483±18 ms•hr; overall p=0.0003, 
p≤0.002, testosterone vs placebo and testosterone vs progesterone; QTFram: 469±23 vs 
477±25 vs 482±17 ms•hr, overall p=0.0005; p≤0.007 testosterone vs placebo and 
testosterone vs progesterone). Progesterone did not significantly affect QTF or QTFram 
AUEC0-1.17 vs placebo.
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Transdermal testosterone also attenuated the AUEC0-8.17, indicating a more prolonged effect 
(QTF: 3255±173 vs 3304±145 vs 3335±142 ms•hr; overall p=0.001, p≤0.02, testosterone vs 
placebo and testosterone vs progesterone; QTFram: 3234±160 vs 3289±146 vs 3328±130 
ms•hr, overall p<0.0001; p≤0.003 testosterone vs placebo and testosterone vs progesterone). 
Progesterone did not significantly influence QTF AUEC0-8.17 versus placebo (p=0.10). 
However, the difference between progesterone and placebo on QTFram AUEC0-8.17 was 
significant (p=0.03). Adverse effects included fatigue (progesterone, n=1) and mild rash 
(transdermal placebo, n=1).
In conclusion, despite a small sample, our results suggest that transdermal testosterone 
attenuates drug-induced QT lengthening in older men. We cannot rule out an effect of oral 
progesterone on attenuation of drug-induced QT lengthening. These findings support larger 
studies investigating the efficacy, safety and feasibility of transdermal testosterone and oral 
progesterone for attenuating drug-induced QT interval lengthening in older men with risk 
factors who require therapy with QT-prolonging drugs.
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Effect of transdermal testosterone and oral progesterone on drug-induced QT interval 
lengthening.
Panel A. Mean QTF intervals during and for 8 hours (± SEM) and 1 hour (inset) after a 10-
minute infusion of ibutilide 0.003 mg/kg in testosterone, progesterone and placebo phases, 
Panel B. Mean QTFram intervals during and for 8 hours (± SEM) and 1 hour (inset) after a 
10-minute infusion of ibutilide 0.003 mg/kg in testosterone, progesterone and placebo 
phases. Panel C. Lead II maximum QTF interval after ibutilide 0.003 mg/kg during 
progesterone, placebo and testosterone phases (mean ± SD), and Panel D. Lead II maximum 
QTFram interval after ibutilide 0.003 mg/kg during progesterone, placebo and testosterone 
phases (mean ± SD).
QTF = Fridericia-corrected QT interval; QTFram = Framingham-corrected QT interval; SD = 
Standard deviation; SEM = Standard error of the mean
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